High demand encourages Sterling Pharma's phased expansion of its US facility

28 Oct 2019

The investment will allow the CDMO to take on new projects, as well as bolster the company's chemistry development capabilities.

CDMO, Sterling Pharma Solutions, is investing $1.5 million into a phased expansion of its US facility in North Carolina.

High demand encourages Sterling Pharma's phased expansion of its US facility

The investment follows the acquisition of the former US CiVentiChem site earlier this year. Over the next 3 years, the company plans to expand the cGMP production suites, add a non-GMP scale-up production facility, expand its QC laboratory and increase the site’s R&D capacity.

Mat Minardi, President US Operations said: “The North American market now makes up 70% of our customer portfolio. And, having expanded our US presence earlier this year with the acquisition of our facility in North Carolina, we have continued to experience strong growth.

“This investment will allow us to continue to meet customer expectations and take on new projects, as well as bolster Sterling’s chemistry development capabilities.

“The specialist capabilities provided by Sterling, particularly our ability to handle challenging chemistries, are in high demand as a result of the increasing complexity of products entering the drug pipeline and the need for more efficient and cost-effective production of APIs. We’re confident this investment will be of huge benefit to our customers.”

The investment plan will also allow Sterling to expand its quality assurance (QA) team to provide more support for cGMP projects, increase its team of chemists and put measures in place to help it secure its US Drug Enforcement Administration (DEA) Schedule I manufacturing approval. This recruitment drive, along with the initial facility expansion, forms the first part of the phased investment.

The facility, located close to Research Triangle Park, supports the development and manufacturing requirements for pre-clinical and early phase clinical supply for volumes from millilitres up to 100-L batches. The team has expertise in medicinal chemistry services, including lead optimisation and parallel synthesis, cGMP analytical services to support testing and release, process development and small-scale API manufacturing.

This latest investment is part of Sterling’s ongoing growth strategy and follows the completion of the majority acquisition of Sterling Pharma Solutions by specialist European healthcare investor, GHO Capital this year.

As part of its expansion plans Sterling is also recruiting for its US BD and sales team.

Read More

Related news

New microbial air sampler addresses continuous monitoring

New microbial air sampler addresses continuous monitoring

14 Nov 2019

The device supports the new EU GMP Annex 1 requirements.

Read more 
GVK Bio continues to see growth tailwinds for 2020 thanks to a ‘crescendo of factors’

GVK Bio continues to see growth tailwinds for 2020 thanks to a ‘crescendo of factors’

13 Nov 2019

China-US trade challenges has led to de-risking by pharma companies.

Read more 
Winners of the 16th Pharma Awards

Winners of the 16th Pharma Awards

11 Nov 2019

Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.

Read more 
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

8 Nov 2019

But personalized medicines will require new logistics and manufacturing systems.

Read more 
SGH Healthcaring unveils its new asthma spacer device

SGH Healthcaring unveils its new asthma spacer device

8 Nov 2019

Zephyr's revolutionary new design improves drug administration and simplifies treatment delivery for better observance.

Read more 
Recipharm expands Indian injectable dosage form capabilities

Recipharm expands Indian injectable dosage form capabilities

7 Nov 2019

Partnership will combine capabilities and expertise in Europe and India to build a new facility dedicated to injectable formulations to supply demand from Europe and overseas territories.

Read more 
Aptar acquires a leader in drug delivery training devices and patient onboarding

Aptar acquires a leader in drug delivery training devices and patient onboarding

6 Nov 2019

Acquisition reflects movement of treatments being administered by patients at home rather than by healthcare providers.

Read more 
Europe predicted to surpass the US in biologic manufacturing capacity by 2023

Europe predicted to surpass the US in biologic manufacturing capacity by 2023

6 Nov 2019

Demand for biological manufacturing is growing faster than capacity growth.

Read more 
SP acquires Spain based global provider of complete sterile filling lines

SP acquires Spain based global provider of complete sterile filling lines

5 Nov 2019

Company's strategic move reflects its expectation of short-run aseptic liquid filling to continue to drive pharmaceutical growth.

Read more 
Legacy recruits heavily to meet growing steriles demand

Legacy recruits heavily to meet growing steriles demand

5 Nov 2019

Company to reach 250 employees by year end to meet growing drug product manufacturing demand.

Read more